Skip to main content

Helix Biopharma Corp(HBP-T)
TSX

Today's Change
Real-Time Last Update
Day Low1.65
Day High1.65
Open:1.65
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Helix Biopharma Corp

Select a category then submit the form to load news
Newsfile
Upcoming Meeting Dates - December 1, 2025
ACCESS Newswire
Helix BioPharma Announces Presentation at Q3 Investor Summit Virtual on 16 September 2025
AI-generated - The Globe and Mail
Helix BioPharma: Bottom 25 Performing Stocks Year-to-Date on TSX (HBP)
Baystreet
Stocks in play: Helix BioPharma Corp.
The Globe and Mail
Helix BioPharma: Top 10 Undervalued Biotechnology Industry Stocks on TSE (HBP)
ACCESS Newswire
Jerzy Wilczewski Announces Acquisition of Common Shares of Helix Biopharma Corp.
ACCESS Newswire
Helix Biopharma Corp. Closes Private Placement
ACCESS Newswire
Helix Biopharma Corp. Announces Fiscal 2022 First Quarter Results
ACCESS Newswire
Helix BioPharma Corp. Extends Period to Exercise Warrants
ACCESS Newswire
Helix BioPharma Corp. Provides Third Bi-Weekly MCTO Status Update
ACCESS Newswire
Helix BioPharma Corp. Provides Second Bi-Weekly MCTO Status Update
ACCESS Newswire
Helix BioPharma Corp. Provides Bi-Weekly MCTO Status Update
ACCESS Newswire
Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer
ACCESS Newswire
Helix BioPharma Corp. Announces Appointment of New Director
ACCESS Newswire
Helix BioPharma Corp. Announces Changes to the Company's Board of Directors and Management
ACCESS Newswire
Helix BioPharma Corp. Announces Appointment of New Auditor and Extends Period to Exercise Warrants
ACCESS Newswire
Helix BioPharma Corp. Announces Fiscal Third Quarter 2021 Results

Profile

Helix BioPharma Corp is a clinical-stage biopharmaceutical company developing therapies in immune-oncology focused on cancer prevention and treatment. The Company is developing a proprietary platform of bio-conjugates targeting hard-to-treat solid tumors over-expressing CEACAM6, including Tumor Defense Breaker, L-DOS47, and three CEACAM6-specific antibody-drug conjugates. Its pre-IND candidates include LEUMUNA, an oral immune checkpoint modulator for hematological malignancies, and GEMCEDA, an oral prodrug of gemcitabine for solid tumors.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.